Sponsor GmbH
Quick facts
Marketed products
- Sunitinib (Sutent) · Oncology
Sunitinib is a multi-targeted tyrosine kinase inhibitor that blocks growth factor receptors (VEGFR, PDGFR, KIT, FLT3) to inhibit tumor angiogenesis and cell proliferation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: